Neuronetics Unveils New Depression Data at Clinical TMS Society’s Virtual Events

Neuronetics, Inc

MALVERN, PA — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, will present clinical data and host virtual educational sessions as part of the Clinical TMS Society’s virtual programming.

The Clinical TMS Society, a professional association that aims to optimize awareness and accessibility of transcranial magnetic stimulation (TMS) therapy, is hosting virtual events this year in place of its traditional Annual Meeting, giving attendees a chance to experience educational sessions remotely. As a sponsor, Neuronetics will present a product theater webinar and two virtual poster presentations detailing the company’s latest research with NeuroStar Advanced Therapy in bipolar and unipolar depression.

On Tuesday, September 29 at 5:30 p.m. PDT (8:30 p.m. EDT), Neuronetics will host a product theater webinar that will address these two topics:

  • Treatment of Bipolar Depression: A Pilot StudyClinical experience has suggested that NeuroStar Advanced Therapy might be effective for bipolar depression. This presentation will review the existing literature on the efficacy of TMS for bipolar depression and present the findings from a two-center open-label prospective trial of NeuroStar Advanced Therapy in bipolar depression including type I and type II patients.
READ:  Neuronetics to Report Third Quarter 2020 Financial and Operating Results

“With so few treatments available for the management of bipolar depression, making TMS a non-drug treatment option could be groundbreaking,” said Dr. Scott Aaronson, Director of Clinical Research at Sheppard Pratt Health System and lead investigator of the study. “Results from this open label pilot study are quite promising and should lead to further efforts to make this treatment available to help as many patients as possible.”

  • Clinical Outcomes of NeuroStar Advanced Therapy Treatment: The Largest Patient Registry for Depression Treatment with Transcranial Magnetic Stimulation—With more than 9,000 patients across more than 100 private practice locations in the U.S., Neuronetics’ Outcomes Registry is the largest registry documenting outcomes for any treatment of Major Depressive Disorder (MDD). This presentation will report new findings from the registry about the efficacy of NeuroStar Advanced Therapy in adult patients treated for an episode of MDD in community settings.

“Findings from Neuronetics’ Outcomes Registry document real-world outcomes, and further demonstrate that NeuroStar Advanced Therapy delivered in the community setting is an effective treatment for depression,” said Dr. Harold A. Sackeim, Professor of Clinical Psychology in Psychiatry and Radiology at the College of Physicians and Surgeons, Columbia University and lead author of the study. “Results from this large registry will help improve depression treatment protocols and treatment plans for individual patients.”

READ:  Exont-based Biopharmaceutical Company Raises $44.9 Million in Initial Public Offering

In addition, the following NeuroStar poster presentations will be on display throughout the duration of the virtual poster session from now through Saturday, October 31:

  • Poster #63: Comparison of Naturalistic Treatment Outcomes with the Standard 38-Minute Protocol vs. Shortened (“DASH”) Protocol: A NeuroStar Registry Database Study—Based on a subset analysis of over 7,700 patients from the NeuroStar Outcomes Registry, data demonstrates that efficacy is statistically similar between patients who received the Standard treatment protocol at 38 minutes per session compared to the DASH protocol at 19 minutes per session.

Dr. Scott West, Medical Director at Nashville NeuroCare Therapy and lead author of the DASH protocol poster commented, “The response rates we’ve seen are comparable between NeuroStar’s standard and DASH treatment protocols, which provide support for a shorter session as an effective treatment solution. Research like this underscores Neuronetics’ commitment to providing safe and effective depression treatments for clinicians and patients.”

  • Poster #10: Post Marketing Rate of Seizures During Transcranial Magnetic Stimulation (TMS) Treatment with NeuroStar Advanced Therapy Is LowIn analyzing the seizure rate from post marketing surveillance and from literature related to Neuronetics-sponsored clinical trials, it was found that the rate of seizures reported during TMS treatments with the NeuroStar Advanced Therapy device was even lower than previously estimated.
READ:  Co-Founder of Chester County-based Biopharmaceutical Company to Speak at 4th Annual Gene Therapy for Rare Disorders Europe Conference

The Clinical TMS Society encourages attendees to register for the virtual events as early as possible. Those interested in attending the webinar can register online here until Monday, September 28. Those interested in viewing poster presentations can register online here.

Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.

Buy Us a Cup of Coffee